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original article

Cost-effectiveness analysis of a system-based
approach for managing neonatal jaundice and
preventing kernicterus in Ontario
Bin Xie PhD, Orlando da Silva MD, Greg Zaric PhD

l’analyse coût-efficacité de l’approche systémique
pour prendre en charge la jaunisse néonatale et
prévenir l’ictère nucléaire en Ontario, au Canada

OBjeCtive: To evaluate the incremental cost-effectiveness of a systembased approach for the management of neonatal jaundice and the prevention of kernicterus in term and late-preterm (≥35 weeks) infants,
compared with the traditional practice based on visual inspection and
selected bilirubin testing.
Study deSiGn: Two hypothetical cohorts of 150,000 term and
late-preterm neonates were used to compare the costs and outcomes
associated with the use of a system-based or traditional practice
approach. Data for the evaluation were obtained from the case costing
centre at a large teaching hospital in Ontario, supplemented by data
from the literature.
ReSultS: The per child cost for the system-based approach cohort was
$176, compared with $173 in the traditional practice cohort. The
higher cost associated with the system-based cohort reflects increased
costs for predischarge screening and treatment and increased postdischarge follow-up visits. These costs are partially offset by reduced costs
from fewer emergency room visits, hospital readmissions and kernicterus
cases. Compared with the traditional approach, the cost to prevent one
kernicterus case using the system-based approach was $570,496, the cost
per life year gained was $26,279, and the cost per quality-adjusted life
year gained was $65,698.
COnCluSiOn: The cost to prevent one kernicterus case using the
system-based approach is much lower than previously reported in the
literature.

OBjeCtiF : Évaluer le rapport coût-efficacité incrémentiel d’une
approche systémique de prise en charge de la jaunisse néonatale et de
prévention de l’ictère nucléaire chez les nourrissons à terme et peu
prématurés (au moins 35 semaines d’âge gestationnel) par rapport à la
pratique classique fondée sur l’inspection visuelle et des tests de
bilirubine sélectionnés.
MÉtHOdOlOGie : Les chercheurs ont utilisé deux cohortes
hypothétiques de 150 000 nouveau-nés à terme et peu prématurés pour
comparer les coûts et les issues associés à l’utilisation d’une approche
systémique ou classique. Les données d’évaluation étaient tirées du
centre de coûts des cas d’un grand centre universitaire de l’Ontario, et
complétées par des données extraites de publications.
RÉSultAtS : L’approche systémique coûtait 176 $ par enfant,
comparativement à 173 $ dans la cohorte de pratique classique. Le
coût dans la cohorte d’approche systémique reflète les coûts plus élevés
du dépistage et du traitement avant le congé et le plus grand nombre
de rendez-vous de suivi après le congé. Il est partiellement compensé
par la réduction des coûts attribuable au moins grand nombre de
consultations à l’urgence, de réhospitalisations et de cas d’ictère
nucléaire. Par rapport à l’approche classique, le coût pour prévenir un
cas d’ictère nucléaire au moyen de l’approche systémique s’élève à
570 496 $, le coût par année de vie gagnée, à 26 279 $, et le coût par
année de vie pondérée par la qualité, à 65 698 $.
COnCluSiOn : Le coût pour prévenir un cas d’ictère nucléaire au
moyen de l’approche systémique est beaucoup moins élevé que ce que
révélaient les publications auparavant.
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Neonatology

N

eonatal jaundice is a common condition among neonates,
affecting approximately 60% of otherwise healthy newborn
infants (1). It is caused by the inability of the infant body to quickly
excrete bilirubin in the blood, with symptoms including yellowing
of the skin and other tissues. In otherwise healthy term or near term
(gestational age ≥ 35 weeks) infants without known risk factors and
whose bilirubin levels indicate low or intermediate risk of developing
hyperbilirubinemia, the condition usually resolves spontaneously
without the need for treatment (2-4). For patients with one or more
known risk factors and/or patients with very high bilirubin levels,
prolonged hyperbilirubinemia can result in bilirubin-induced neurological dysfunction (BIND) or, in the most severe cases, kernicterus
(2-4). In these patients, timely treatment with phototherapy or
exchange transfusions is crucial (5).
In response to evidence that kernicterus cases may be on the
rise (6-7), a system-based approach to manage neonatal jaundice
and prevent kernicterus (8) was recommended by several

professional agencies, including the American Academy of
Pediatrics (2) and the Canadian Paediatric Society (3). Key elements of this approach include universal bilirubin screening and
individualized postdischarge follow-up care based on results of
such screening. Although this approach seems intuitive, acceptance is not universal. The growing, but still limited, evidence to
support its efficacy and cost-effectiveness have led to legitimate
debate (4,9,10). For example, while there are a few cost-effectiveness
studies evaluating various elements of the management of neonatal jaundice (11) and the prevention of kernicterus (11-12), we
are not aware of any direct economic evaluation comparing the
system-based approach with the traditional approach.
In the present study, we present an economic evaluation of the
cost-effectiveness of a system-based approach for the management of
neonatal jaundice and the prevention of kernicterus compared with
the traditional approach. The evaluation includes all major components of the system-based approach and offers a direct comparison
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Table 1
Input values used in the evaluation
Traditional cohort
Resource use

Value

Predischarge phototherapy

4.25

Predischarge exchange transfusion

System cohort
Value

Reference(s)

LHSC,15

4.8

20

0.03

15

0.035

23

Morbidity from exchange transfusion

5.0

16

5.0

2,24

Predischarge bilirubin measured

25.1

Assumption

100

20

Early and more intensive follow-up scheduled (ie, high risk)

10.0

20

13.0

21

Attend early and more intensive follow-up visits

82.4

8

82.4

13

2

8

2

13

Bilirubin measurement at follow-up visits for high-risk patients

50.0

Assumption

100

13

Attend routine follow-up

53.0

17

53.0

25

Bilirubin measurement at routine follow-up visit

1.3

18, 21

1.3

26,27

Probability of emergency room visit

1.87

LHSC

1.46

20

Probability of readmission

0.49

LHSC

0.38

20

Probability of kernicterus

0.002

8,15,20

0.0014

30

Number of visits for high risk infants, mean

Reference(s)

Costs, $
Predischarge bilirubin measurement

1.11

LHSC

1.11

20

Predischarge phototherapy

2,012.16

LHSC

2,012.16

20

Predischarge exchange transfusion

8,903.50

LHSC

8,903.50

20

29,854.00

LHSC

29,854.00

20

Average cost of morbidity from exchange transfusion
Follow-up visit
Bilirubin measurement at follow-up visit
Emergency room visit
Readmission
Kernicterus

56.10

25

56.10

34

5.00

25

5.00

34
20

262.36

LHSC

262.36

3,240.34

LHSC

3,240.34

20

1,329,388.71

35

1,329,388.71

26

Data presented as % unless otherwise indicated. Costs reported as 2008 Canadian dollars. LHSC London Health Sciences Centre, London, Ontario

between the system-based approach and the traditional approach. We
included incremental costs, incremental kernicterus cases, cost per
kernicterus cases prevented and cost per life year gained as outcomes.
While the main analyses were based on the public payer’s perspective,
we also reported results based on societal perspective in sensitivity
analyses.

MetHOdS
Patient cohorts
The costs and outcomes of two hypothetical cohorts of 150,000
(the approximate number of newborns each year in Ontario)
otherwise healthy, term or near term infants in Ontario, were compared. One cohort experienced the system-based approach to
12

jaundice management and kernicterus prevention (the ‘system’
cohort), and the other experienced the traditional approach (the
‘traditional’ cohort). Graphic illustrations of these two approaches
are presented in Figures 1A and 1B. Figure 1A illustrates the treatment regimens before discharge for both cohorts, and Figure 1B
illustrates the treatment regimens after discharge for both cohorts.
The differences between the two approaches lie in the probability
values, as presented in Table 1.
In both cohorts, bilirubin measurements and referral of infants
for readmission to initiate treatment during follow-up visits were
at the discretion of family doctors or paediatricians. Parents could
also bring their infants to the emergency room, and infants could
be readmitted from the emergency room if necessary.
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Figure 1) A Schematic illustration of the two approaches (before discharge). B Schematic illustration of the two approaches (after discharge)

analysis of system-based management

data and sources
Parameter estimates and sources are summarized in Table 1. All
costs are in 2008 Canadian dollars.

System cohort
Resource use data for the system cohort were derived from the literature. For the probability of predischarge treatment, several studies reported an increase in predischarge treatment rate following
implementation of a system-based approach. For example, Mah et al
(14) reported an increase of 11.3% (from 4.4% to 5.1%). Assuming
the same increase from the 4.25% treatment rate in the LHSC
cohort, results in a treatment rate of 4.8% (4.25% × 1.113) in the
system cohort. This rate is comparable with rates reported elsewhere (17,20).
It was assumed that earlier and more intense follow-up would
be arranged for 13% of infants (20). It was also assumed that bilirubin levels would be measured in all infants with early and
intense follow-up because such measurements can be used with
predischarge measurements to accurately assess the risk for hyperbilirubinemia or kernicterus. The probability of actually being
followed-up for these high- or intermediate-to-high-risk patients
was assumed to be the same as the traditional cohort. The
remaining infants would receive routine follow-up, with the
same probability of actually being followed-up as in the traditional cohort.
For resource use of emergency room visits and hospital readmissions, several studies reported a decrease in hyperbilirubinemiarelated readmissions. For example, Eggert et al (21) reported a
21.8% decrease in readmission rate (from 0.55% to 0.43%) after
the implementation of a universal screening program. An emergency room visit rate of 1.46% (1.87% × [1−0.218]) and a readmission rate of 0.38% (0.48% × [1−0.218]) in the system cohort was
assumed. This readmission rate is similar to those reported in the
literature (9,21).
Paediatr Child Health Vol 17 No 1 January 2012

bilirubin level
below
hyperbilirubinemia

Total

0.00125*
(0.002%×62.5%)

0.00075

0.002†

6.09875

93.89925

99.998

6.1

93.9

100

0.00072
(0.00125%× [1-42.3%])

0.00075

0.00147

Normal

3.519

96.479

99.9985

Total

3.52

96.48

100

Hyperbilirubinemia
Traditional cohort
Kernicterus
Normal
Total
System cohort
Kernicterus

Reduction rate

26.4‡

Data presented as %. *The percentage of infants in the traditional cohort who
had both kernicterus and hyperbilirubinemia; †The percentage of infants in the
traditional cohort who developed kernicterus; ‡The reduction rate is calculated
as (0.002%-0.00147%)/0.002%

There is no evidence that directly links the system-based
approach to a reduction in the rate of kernicterus cases. The conservative assumption was made that the system-based approach
reduces the kernicterus case rate only through reducing hyperbilirubinemia cases. More specifically, it was assumed that 62.5% of all
kenircterus cases would have bilirubin levels above the 95th percentile (13). A further assumption that the system-based approach
would reduce the incidence of hyperbilirubinemia by 42.3% was
made (14). Assuming a hyperbilirubinemia rate of 6.1% (17), this
would translate into a 26.4% reduction in the rate of kernicterus
cases (see Table 2 for details).
Due to the very limited survival data for kernicterus patients,
life expectancy was approximated using survival data for cerebral
palsy (CP) patients (22). A Gompertz function was fitted (23)
using these survival data and the life tables for Ontario (24).
Utilities for CP patients reported in the literature (25) were also
used to calculate quality-adjusted life years (QALYs).
Possible negative consequences of the system-based approach
include potential harm from phototherapy such as weight loss,
gastrointestinal problems, interruption of breastfeeding and disruption of the maternal-infant relationship, possible growth of melanocytic nevi and significant morbidity due to exchange transfusion (4).
Only the costs due to morbidity from exchange transfusion were
included in the analysis, becasue a public payer perspective was
taken and it was assumed that the potential harm from phototherapy would be temporary and would not cost the public payer.
Costs
Cost data for predischarge bilirubin measurements, predischarge
hospital treatments, exchange transfusion-related morbidity, emergency room visits and readmissions were obtained from the case
costing centre at LHSC. The costs for predischarge treatment
include costs due to prolonged hospital stay. Costs for follow-up
visits and laboratory tests were obtained from the 2008 Ontario
Health Insurance Plan (OHIP) fee schedule (26). The lifetime
medical cost for kernicterus was obtained from the literature (27).

ReSultS
Base case analysis
Results for the base case analysis are presented in Table 3.
Overall, the system-based approach was more costly (total cost
was $452,000 higher for the entire cohort, or $3 per child).
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traditional cohort
Resource use for hospital-related services for the traditional cohort,
including bilirubin measurements, treatments with phototherapy
or exchange transfusion, emergency room visits and readmissions,
were based on a cohort of 2630 healthy term or late-preterm
infants delivered at the London Health Sciences Centre (LHSC)
in London, Ontario, from January 1, 2008 to December 31, 2008,
or were obtained from secondary sources. LHSC is one of two hospitals in the London region that handles the vast majority of deliveries.
The system-based approach was not implemented at the time of data
collection. LHSC has the only paediatric emergency room in the city
and handles readmissions for all infants delivered at the hospital.
An exchange transfusion rate of 0.03%, as reported by Seidman et al
(15) was used, and a 5% morbidity rate from exchange transfusion was
assumed, as reported in the literature (2). The morbidity due to
exchange transfusion was assumed to be short-term only; therefore
such morbidity only impacted the costs component of the
analysis.
It was further assumed that during these routine follow-up visits, 2.2% of infants would show signs of jaundice, as Bhutani et al
(17) reported that 2.2% of infants whose bilirubin level was below
the high-risk zone would move to the high-risk zone at follow-up,
and that bilirubin measurements would be ordered in 57.7% of
these infants (18). This means that the probability of bilirubin
measurement for all infants at routine follow-up visits would be
1.3% (57.7% × 2.2%).
There have been no kernicterus cases at LHSC during the period of data collection, so the rate reported in Canada (19), one in
50,000 live births, was used in the evaluation.

Table 2
Kernicterus reduction rate calculations

Xie et al

Table 3
Results of the base case analysis

Table 4
Selected results for one-way sensitivity analysis

Traditional
cohort

System
cohort

Difference

Cost per kernicterus case prevented, $

–

570,496

–

Treatment rate of the traditional cohort*

Life years gained

–

17.2

–

3.0%

Cost per life year gained

–

26,279

–

4.0%

1,522,061

452,000

5.0%

–2,288,847

6.0%

–6,099,756

Item

Total cost

25,897,000 26,349,000

Cost per child

Cost per kernicterus case
prevented, $
5,332,970

173.00

176.00

3.00

Per child cost before discharge

101.50

89.10

12.40

Per child cost in follow-up visits

39.00

36.40

2.60

0%

3.80

4.90

–1.10

10%

94,133

Per child cost in readmission

12.30

16.00

–3.70

20%

1,713,769

Per child cost in kernicterus

19.40

26.60

–7.20

Cost per bilirubin measurement

Per child cost in emergency room visit

Rate of increase in treatment rate with system approach
–1,525,503

553,105

$5

1,143,256

$10

1,880,945

However, the system-based approach prevented 0.8 kernicterus
cases and gained 17.2 life years or 6.88 QALYs, resulting in a cost
per kernicterus case prevented of $570,496, a cost per life year
gained of $26,279 and a cost per QALY gained of $65,698.

$20

3,356,324

Sensitivity analysis
The analyses were performed from a societal perspective, using the
economic cost to society for a child with kernicterus (28) and
other nonmedical costs such as transportation and lost productivity
of the parents (29). The system-based approach would achieve a
cost-savings of $597,527 per kernicterus case prevented, compared
with the traditional approach. The main driver is the high societal
cost for kernicterus cases. Given the lack of data, the potential
costs associated with the transmission of bilirubin results and
arranging for a follow-up are not included in the analysis.
Several costs were varied, including costs for biliburin measurements, follow-up visits, emergency visits, hospital treatments,
readmissions and the lifetime costs of kernicterus, in the sensitivity
analysis. Key effectiveness data, including reduction rates in treatment, readmission and kernicterus cases due to the system-based
approach, were also varied. One-way and multiway sensitivity
analyses for these variables were performed.
Results for one-way sensitivity analysis are presented in Table 4.
The analysis found that the cost per kernicterus case prevented
was very sensitive to the cost of bilirubin measurement, the rate of
change in treatment rate, and baseline kernicterus case rate or
kernicterus case reduction rate.
Results of the multiway sensitivity analysis are presented in Table 5.
The analysis found that the system-based approach would achieve
cost-savings under a wide range of values for other parameters if the
reduction rate for kernicterus cases was above 50%.

Kernicterus rate in the traditional cohort
–303,450

1 in 27,000
1 in 40,000

190,519

1 in 80,000

1,710,428

1 in 100,000

2,470,382

Reduction rate in kernicterus cases
10%

3,686,309

40%

–75,464

70%

–612,860

100%

–827,818

Costs reported as 2008 Canadian dollars. *Assuming that the treatment rate of
the system-based approach would remain constant

diSCuSSiOn

The advantages of the system-based approach lie in its ability to
timely and accurately identify, treat and follow up infants at high
risk of developing hyperbilirubinemia, therefore reducing the
number of cases of BIND or kernicterus (8). Apart from reducing
kernicterus cases, the system-based approach may also reduce emergency room visits and readmissions (21). However, the system-based
approach can be costly because it involves more bilirubin measurements, more aggressive treatment and more follow-up visits.
In the present study, we found that the system-based approach
was more costly than the traditional approach, but also more
effective in preventing kernicterus. The cost per life year gained
was $26,279, and the cost per QALY gained was $65,698, which is
well within the range accepted for screening tests in the perinatal
period (30). The cost to prevent one case of kernicterus is
$570,496, which is lower than the lifetime medical cost of caring
for a child with kernicterus (27).

Table 5
Selected results for multiway sensitivity analysis
Treatment rate of the
traditional cohort

Rate of change in
treatment rate

Readmission rate of
the traditional cohort

Rate of change in
readmission rate

Kernicterus rate in
the traditional cohort

Reduction rate in
kernicterus case

3.0

0

4.0

10

6.0

Cost per kernicterus
case prevented, $

0.3

0

1 in 2,7000

30

–1,101,788

0.4

10

1 in 4,0000

50

–586,877

10

0.6

20

1 in 6,0000

60

–258,044

4.0

10

0.3

20

1 in 10,0000

70

–96,056

3.0

20

0.6

5

1 in 4,0000

40

33,586

4.0

20

0.5

10

1 in 6,0000

60

371,211

6.0

20

0.4

10

1 in 8,0000

90

926,493

5.0

15

0.5

15

1 in 8,0000

50

1,100,984

5.0

20

0.5

25

1 in 10,0000

30

4,870,632

Data reported as % unless otherwise indicated. Costs reported as 2008 Canadian dollars
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$1

Data reported as 2008 Canadian dollars unless otherwise indicated. Cohort
size is 150,000

analysis of system-based management
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would be different from that reported in our analysis if the experiences of the system-based approach at LHSC are different.
Another limitation was the exclusion of some elements of the
management of neonatal jaundice that are practiced with varying
degrees in some communities, such as home phototherapy (34).
Due to the lack of data on the prevalence, efficacy and costs of
such treatments, they were excluded in the analysis. Our results
may not be applicable to communities where these alternative
treatment options are widely practiced.

COnCluSiOn

Given that kernicterus is a preventable disease, we believe that it
is economically justifiable to implement the system-based approach
in communities with similar cost structures as presented in our
analysis.
ACKnOWledGeMentS: The authors thank Dr Randy Welch
and the case costing group at London Health Sciences Centre for their
assistance in accessing the datasets used in this article. The authors
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The cost to prevent one case of kernicterus in our study was
much lower than those reported in the literature. For example,
Suresh et al (12) reported a cost of more than $5 million to prevent
one case of kernicterus. There are three main reasons for the dramatic differences between our results and those from Suresh et al
(12).
First, we included the costs of subsequent emergency room visits and readmissions, whereas Suresh et al did not. We believe that
including the costs of emergency room visits and readmissions can
provide a more comprehensive evaluation because hyperbilirubinemia is the most common cause of neonatal readmission to
hospitals in North America (31), and the system-based approach
has been shown to reduce emergency room visits and readmissions
(21). Given the high costs of such readmissions, the impact on the
incremental cost-effectiveness would be significant. This is demonstrated by Paul et al (11), who reported significant cost-savings
using a home nurse visit program, which was largely driven by the
reduction in emergency room visits and readmissions.
Second, our analysis used costs from a Canadian institution,
which may be lower than the United States institution used in
Suresh et al (12). For example, the cost for predischarge bilirubin
measurment was only $1.11 in our analysis, based on data provided
by the LHSC case costing group, but was assumed to be $20 in
Suresh et al (12). Given that this test would be performed for
every neonate in the system-based approach, a difference of this
magnitude would have major implications for the result. When we
changed the cost to $20 in the sensitivity analysis, the cost to
prevent one kernicterus case increased to approximately $3 million, which is more in line with the estimate of Suresh et al (12).
Third, some of the probabilities in our analysis were different
from those in Suresh et al (12). For example, the reduction rate of
kernicterus cases used in our analysis was much lower than the
70% reduction rate used in Suresh et al (12). Another example is
that we used one in 50,000 as the prevalence of kernicterus cases,
based on the most reliable study in Canada, whereas they used one
in 100,000, based on United States data.
We used total serum biliburin measurements in the main analyses; another possible measurement of biliburin level is transcutaneous bilirubin measurement (TcB), whose properties are well
established and considered to be suitable for screening purposes.
Given that TcB is more costly than total serum biliburin measurements (32), the cost per kernicterus case prevented would be
$1,544,559, assuming that using TcB will not result in any change in
other parameter values in the model. While it is currently more
costly to use TcB, it is more convenient, and if the cost of TcB goes
down, it may become an even more appealing option.
It has been suggested that one of the reasons for the rise in
kernicterus cases or jaundice-related emergency room visits was
the reduced length of stay after delivery (31). The older ‘traditional’ approach, in which babies were kept in hospital throughout most of the risk period for jaundice (and kernicterus), would be
very effective in managing neonatal jaundice and preventing kernicterus; however, the medical costs would also be significantly
higher given the high cost of hospital stays. Given the trend of
decreasing length of stay after birth (33), it is especially important
to have an effective strategy, such as the system-based approach, to
manage neonatal jaundice and prevent kernicterus.
There are some limitations to the present study. Our analysis
was based on Canadian data, so our results may not apply to other
countries. The fact that the data for the system cohort were taken
from the literature and not from the same institution where the
data for the traditional cohort were taken, leaves open the possibility that the cost-effectiveness of the system-based approach
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